Tirzepatide produces some of the largest average weight losses ever recorded for an obesity medication. In the SURMOUNT-1 trial, adults with obesity (without diabetes) lost an average of about 20.9 percent of their body weight on the 15 mg weekly dose over 72 weeks. In SURMOUNT-2, adults with type 2 diabetes lost about 15.7 percent. Real-world results vary widely, and weight regain is common after stopping.
What Tirzepatide Is and Why Results Differ
Tirzepatide is a once-weekly injectable medication sold under two brand names: Mounjaro (FDA-approved for type 2 diabetes) and Zepbound (approved for chronic weight management). It is a dual agonist of two gut hormones, GLP-1 and GIP, which together reduce appetite, slow gastric emptying, and improve insulin secretion. Compared with single-hormone GLP-1 medications like semaglutide, the dual action produces larger average weight loss in head-to-head studies. For background on how the drug class works, see our companion treatment hub.
The SURMOUNT Trials: What the Data Show
The pivotal SURMOUNT clinical trial program tested tirzepatide in different populations and scenarios.
SURMOUNT-1 (Obesity, No Diabetes)
Published in the New England Journal of Medicine in 2022, SURMOUNT-1 enrolled 2,539 adults with a body mass index of 30 or higher (or 27 plus a weight-related condition). Participants were randomized to weekly tirzepatide 5, 10, or 15 mg or placebo for 72 weeks. Mean weight loss results:
- 5 mg: -15.0 percent
- 10 mg: -19.5 percent
- 15 mg: -20.9 percent
- Placebo: -3.1 percent
About 50 percent of people on the highest dose lost at least 20 percent of their body weight, and about 36 percent lost at least 25 percent.
SURMOUNT-2 (Obesity Plus Type 2 Diabetes)
SURMOUNT-2 enrolled adults with both obesity and type 2 diabetes. After 72 weeks, mean weight loss was 12.8 percent on 10 mg and 14.7 percent on 15 mg, compared with 3.2 percent on placebo. Average results were lower than in SURMOUNT-1 because diabetes typically blunts weight-loss responses to any intervention.
SURMOUNT-3 (Tirzepatide After Intensive Lifestyle Therapy)
SURMOUNT-3 first put participants through 12 weeks of intensive lifestyle therapy, then randomized those who lost at least 5 percent to either tirzepatide or placebo for an additional 72 weeks. The tirzepatide group lost an additional 18.4 percent on top of the lifestyle losses. The placebo group regained about 2.5 percent.
SURMOUNT-4 (Maintenance and Regain)
SURMOUNT-4 addressed a critical question: what happens when you stop the medication? After 36 weeks of open-label tirzepatide (during which participants lost an average of 20.9 percent), they were randomized to either continue tirzepatide or switch to placebo. Over the next 52 weeks:
- The continued tirzepatide group lost an additional 5.5 percent.
- The placebo group regained 14.0 percent.
This study underlined what most clinicians and researchers expected: tirzepatide and other obesity medications generally need to be taken long-term, similar to medications for high blood pressure or high cholesterol.
What Trial Averages Look Like in Practice
| Starting Weight | 15% Loss | 20% Loss | 25% Loss |
|---|---|---|---|
| 200 lb | 30 lb (170 lb) | 40 lb (160 lb) | 50 lb (150 lb) |
| 250 lb | 37.5 lb (212.5 lb) | 50 lb (200 lb) | 62.5 lb (187.5 lb) |
| 300 lb | 45 lb (255 lb) | 60 lb (240 lb) | 75 lb (225 lb) |
Trial averages are useful as expectations, but individual results vary substantially. Some people lose noticeably more or less than the trial mean.
Real-World Results: Larger Variation Than Trials
Outside of clinical trials, results are typically smaller and more variable. Reasons include:
- Dose escalation issues: Side effects like nausea may slow or stall escalation to higher doses.
- Inconsistent adherence: Missed weekly doses reduce average effect.
- Insurance interruptions: Coverage changes or shortages can force pauses.
- Different lifestyle context: Trial participants typically receive nutrition counseling and behavioral support not available outside trials.
- Compounded versions: Pharmacy-compounded tirzepatide may not match the brand-name product in dose accuracy or quality.
Real-world studies of GLP-1 medications consistently show smaller mean weight loss than registration trials, often 60 to 75 percent of the trial average over the same time period.
Beyond the Scale: Other Outcomes
Tirzepatide has also been associated with improvements in cardiovascular risk factors:
- Lower systolic blood pressure (typically 5 to 8 mm Hg)
- Lower triglycerides (often 25 to 30 percent reduction)
- Lower LDL cholesterol (modest reduction)
- Improved glucose control and lower A1C in people with diabetes or prediabetes
- FDA approval for moderate to severe obstructive sleep apnea (Zepbound, 2024)
For more on how prediabetes management ties into broader cardiometabolic health, see our prediabetes 101 hub.
About Those Before-and-After Photos Online
Social media is full of dramatic before-and-after tirzepatide photos. Use them with caution:
- Photos often do not specify the dose, duration of treatment, or whether the medication was brand-name or compounded.
- Lighting, posture, and clothing dramatically change perceived results.
- Influencer images may be sponsored.
- Cherry-picked outcomes can create unrealistic expectations.
Trial averages are a more honest reference. Most people will see noticeable changes in body shape and clothing fit at 8 to 12 percent weight loss; the largest visual changes happen above 15 percent.
Common Side Effects to Plan For
The most frequent side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and reduced appetite. They are typically worst during dose escalation and improve with time. Less common but serious risks include pancreatitis, gallbladder problems, and rare bowel obstruction. Tirzepatide is contraindicated in people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
Setting Realistic Expectations
If you and your clinician decide tirzepatide is appropriate, plan for a long horizon. Average weight loss continues to accumulate through about 16 to 18 months before plateauing. Stopping the medication usually leads to gradual regain. The most successful long-term results come from combining the medication with lasting changes in eating patterns, physical activity, and sleep.
The Bottom Line
Tirzepatide is one of the most effective weight-loss medications ever studied, with average losses around 21 percent in adults with obesity and 15 percent in those with type 2 diabetes. Real-world results vary, regain after stopping is common, and side effects need to be managed. Tirzepatide is a powerful tool, not a quick fix. Discuss whether it fits your goals, medical history, and budget with a clinician who can supervise dose, monitoring, and lifestyle support.
